Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy
Related Posts
Ennin E, Mallepally N, Dodge JL, Dara L. Authors' Reply on Immune-Mediated Liver Injury in HCC. Liver Int. 2025 Nov;45(11):e70415. doi: 10.1111/liv.70415. PMID: 41122960.
Prommer EE. Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist. J Opioid Manag. 2025 Sep-Oct;21(5):377-387.[...]
Gresham G, Henry NL, Bandos H, Calsavara VF, Cecchini RS, Diniz MA, Hays RD, Luu M, Kim S, Rogatko A, Yothers G, Ganz PA, Tighiouart[...]